Quick Links

Accreditation/Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Ultragenyx Pharmaceutical Inc.

Clinical BriefingsTM: X-Linked Hypophosphatemia: Diagnosing and Addressing the Underlying Cause of the Disease

Release Date: December 31, 2018
Expiration Date: December 31, 2019
Media: Internet - based

Activity Overview

X-linked hypophosphatemia (XLH) is a lifelong condition that requires long-term treatment and monitoring. Clinical presentation is variable, causing significant morbidity in patients with XLH as they age. This morbidity may result from impairment in mobility, osteoarthritis, enthesopathy, stress fractures in weakened bones, and pain and discomfort. There are no official guidelines for the treatment of XLH, therefore, additional complications can occur due to incorrect or inadequate treatment and or misdiagnosis. This activity is designed to update healthcare professionals on diagnosis for early recognition of XLH, and the evolving landscape of treatment options in the management of XLH in order to improve outcomes and patient satisfaction.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Ultragenyx Pharmaceutical Inc.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME/CE certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This online educational activity is directed toward primary care physicians, pediatricians, endocrinologists, nephrologists, dentists, nurse practitioners (NPs), physician assistants (PAs), nurses and other healthcare professionals who would be involved in the diagnosis and management of XLH.

Educational Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Utilize clinical trial data concerning novel therapy for X-linked hypophosphatemia (XLH) in clinical care of patients
  • Evaluate the medical needs of patients with XLH and appropriate multidisciplinary approach to care
  • Apply the knowledge of adverse drug reactions, toxicities, and relative risks of pharmacologic and nonpharmacologic therapies to select appropriate interventions

Faculty, Staff, and Planners' Disclosures


Thomas O. Carpenter, MD
Professor of Pediatrics
Professor of Orthopedics and Rehabilitation
Yale University School of Medicine
New Haven, Connecticut

Disclosures: Grant/Research Support: Ultragenyx Pharmaceutical (Investigator in clinical trials) Consultant: Clementia, Inozyme, Pharmacosmos, Ultragenyx Pharmaceutical Spouse’s employment role: Consultant for Thermo-Fisher Investigational/Off-Label Use of Drugs/Devices Disclosure: Alfacalcidol; Calcitriol; various oral phosphate salts

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields

Become a Member

Forgot Password?
Calendar of Events
Filter By